EU/3/03/145: Orphan designation for the treatment of pancreatic cancer

Rubitecan

Table of contents

Overview

On 10 June 2003, orphan designation (EU/3/03/145) was granted by the European Commission to Eurogen Pharmaceuticals Limited, United Kingdom, for rubitecan for the treatment of pancreatic cancer.

Key facts

Active substance
Rubitecan
Intended use
Treatment of pancreatic cancer
Orphan designation status
Positive
EU designation number
EU/3/03/145
Date of designation
10/06/2003
Sponsor
Eurogen Pharmaceuticals Ltd
The Gloucestershire Innovation Centre
Southgate House
Southgate Street
Gloucester GL1 1UD
United Kingdom
Telephone: +44 (0)1452 563 026
Telefax: +44 (0)1452 563 028
E-mail: Ljohnson@eurogenpharma.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating